CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma.

MLA

Zhou, Xiaoxi, et al. “CD19/CD22 CAR-T-Cell Cocktail Therapy Following Autologous Transplantation Is an Optimizing Strategy for Treating Relapsed/Refractory Central Nervous System Lymphoma.” Experimental Hematology & Oncology, vol. 13, no. 1, Oct. 2024, pp. 1–6. EBSCOhost, https://doi.org/10.1186/s40164-024-00538-y.

APA

Zhou, X., Yu, Q., Dai, Z., Wang, J., Li, C., Huang, L., Zhang, Y., & Cao, Y. (2024). CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma. Experimental Hematology & Oncology, 13(1), 1–6. https://doi.org/10.1186/s40164-024-00538-y

Chicago

Zhou, Xiaoxi, Qiuxia Yu, Zigang Dai, Jue Wang, Chunrui Li, Liang Huang, Yicheng Zhang, and Yang Cao. 2024. “CD19/CD22 CAR-T-Cell Cocktail Therapy Following Autologous Transplantation Is an Optimizing Strategy for Treating Relapsed/Refractory Central Nervous System Lymphoma.” Experimental Hematology & Oncology 13 (1): 1–6. doi:10.1186/s40164-024-00538-y.